Norwegian immuno-oncology specialist Targovax has appointed Oystein Soug as its new chief executive officer following the resignation of Gunnar Gåardemyr.
Formerly chief financial officer, Soug joined Targovax in 2015 bringing over 20 years of financial management experience to the role.
He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods company.
Jónas Einarsson, chairman of Targovax’s board of directors, said: “We are delighted to announce the appointment of Oystein as the new chief executive officer of Targovax.
“He has played a key role as chief financial officer over the past year – successfully guiding us on the path to becoming a publicly-listed company, securing funding for further development of the company’s ongoing and planned trials.
“We are confident in his ability to lead the company as we approach important milestones in 2017 and 2018 in our innovative clinical pipeline designed to help the patient’s own immune system fight cancer.”